Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients

BACKGROUND: To identify whether circulating levels of angiogenesis-related factors may be predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) patients. METHODS: Pre-treatment serum levels of 24 cytokines were measured using a multiplex bead assay (MBA) in 32 pre-tre...

Descripción completa

Detalles Bibliográficos
Autores: Abajo, A. (Ana)|||/items/c42869a7-1f26-4d83-920a-d0346c8defef, Boni, V. (Valentina)|||/items/1393d11a-f436-4221-8cf3-ae8391a55b24, Lopez, I. (Inés)|||/items/0353c30a-047c-4379-8b4e-98084ec19f11, Gonzalez-Huarriz, M. (Marisol)|||/items/00a6d7fb-7851-4264-bdfd-9172d60bc40b, Bitarte, N. (Nerea)|||/items/56b04cbb-c7a5-4fd2-9489-107e2322b76f, Zarate, R. (Ruth)|||/items/08593a15-ef00-4db2-bf43-3e6e4c3d5161, Rodríguez-Rodríguez, J. (Javier)|||/items/eb216e0c-3040-4db1-82a3-45514feafb00, Garcia-Foncillas, J. (Jesús)|||/items/f9f291e8-e98b-4de1-ab28-9d44e04f8a09, Bandres, E. (Eva)|||/items/a8f1d140-44cc-4ffe-8a76-3e49c4b4f78c
Tipo de recurso: artículo
Fecha de publicación:2012
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/36169
Acceso en línea:https://hdl.handle.net/10171/36169
Access Level:acceso abierto
Palabra clave:Bevacizumab
Serum biomarkers
Colorectal cancer
Multiplex bead assays
Descripción
Sumario:BACKGROUND: To identify whether circulating levels of angiogenesis-related factors may be predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) patients. METHODS: Pre-treatment serum levels of 24 cytokines were measured using a multiplex bead assay (MBA) in 32 pre-treated mCRC patients treated with irinotecan plus bevacizumab-based salvage therapy. Macrophage-derived chemokine (MDC), interleukins (ILs) 8 and 6 levels were also validated by enzyme-linked immunosorbent assay (ELISA) at different time points during therapy. RESULTS: Higher epidermal growth factor (EGF) and MDC baseline levels (2.2- and 1.4-fold, respectively) and lower IL-10, IL-6 and IL-8 levels (0.2-, 0.6-, and 0.6-fold, respectively, P<0.05) were observed in patients responding to therapy. Baseline levels of these five serum factors compose a risk signature that may define the subset of patients most likely to benefit from bevacizumab-based therapy in terms of response rate and survival times. A positive correlation was found between MBA and ELISA results (P<0.01). Treatment exposure increased MDC and had opposite effects on IL-8 levels, which were decreased (P<0.05). CONCLUSION: This study suggests that a set of inflammatory and angiogenesis-related serum markers may be associated with the efficacy of bevacizumab-containing regimen.

Similares en LA Referencia